Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 20, 2025 07:00 ET | Source: Wugen

Wugen Announces Dosing of First Patients in Pivotal Trial of Off-the-Shelf, Allogeneic, CD7-Targeted CAR-T Cell Therapy WU-CART-007

Wugen Announces Dosing of First Patients in Pivotal Trial of Off-the-Shelf, Allogeneic, CD7-Targeted CAR-T Cell Therapy WU-CART-007
February 26, 2025 07:00 ET | Source: Wugen

Wugen Announces Appointment of Jim Faulkner, Ph.D., as Chief Technology Officer

Wugen Announces Appointment of Jim Faulkner, Ph.D., as Chief Technology Officer
December 05, 2024 11:26 ET | Source: Wugen

Wugen to Present Clinical Data at the 2024 ASH Annual Meeting Ahead of Pivotal Trial Launch of Off-the-Shelf, Allogeneic, CD7-Targeted CAR-T Cell Therapy WU-CART-007

Wugen to Present Clinical Data at 2024 ASH Meeting Ahead of Pivotal Trial Launch of Off-the-Shelf, Allogeneic, CD7-Targeted CAR-T Cell Therapy WU-CART-007
November 12, 2024 07:05 ET | Source: Wugen

Cherry T. Thomas, M.D., Joins Wugen as Chief Medical Officer, Bringing Cell Therapy Expertise Across Clinical Development, Regulatory, and Medical Affairs as the Company Embarks on a Pivotal Trial for its Investigational, Allogeneic CD7-Targeted CAR-T Cell Therapy

Cherry T. Thomas, M.D., Joins Wugen as Chief Medical Officer, Bringing Cell Therapy Expertise Across Clinical Development, Regulatory, and Medical Affairs
November 12, 2024 07:00 ET | Source: Wugen

Wugen to Initiate a Pivotal Trial for Its Investigational, Off-the-Shelf, Allogeneic, CD7-Targeted CAR-T Cell Therapy, WU-CART-007, in Patients with Relapsed or Refractory T Cell Acute Lymphoblastic Leukemia or T Cell Lymphoblastic Lymphoma

Wugen to Initiate a Pivotal Trial for Its Investigational, Off-the-Shelf, Allogeneic, CD7-Targeted CAR-T Cell Therapy, WU-CART-007
June 14, 2024 07:30 ET | Source: Wugen

Phase 2 Findings Show Wugen’s Investigational Allogeneic CAR-T, WU-CART-007, Was Highly Effective and Surpassed Standard of Care in Treating Hard-to-Treat T-ALL/LBL; Data Presented Today at European Hematology Association (EHA) 2024 Hybrid Congress

Wugen Presents Data at European Hematology Association (EHA) 2024 Hybrid Congress
May 20, 2024 07:03 ET | Source: Wugen

Wugen Announces RMAT and PRIME Designations for WU-CART-007 to Accelerate Regulatory Reviews and Plans to Present Positive Phase 2 Study Findings at European Hematology Association (EHA) 2024 in June

Wugen Announces RMAT and PRIME Designations for WU-CART-007 and Plans to Present Positive Phase 2 Study Findings at EHA 2024
January 03, 2024 08:00 ET | Source: Wugen

Wugen Strengthens Executive Leadership Team with Appointment of Keith Vendola, M.D., M.B.A. as Chief Financial Officer

Wugen Strengthens Executive Leadership Team with the Appointment of Keith Vendola, M.D., M.B.A. as Chief Financial Officer
December 11, 2023 15:00 ET | Source: Wugen

Wugen Presents Latest Data from First-In-Human Phase 1/2 Trial of WU-CART-007 in Patients with Difficult-to-Treat Blood Cancers at American Society of Hematology Annual Meeting

Wugen Presents Latest Data from First-In-Human Phase 1/2 Trial of WU-CART-007 in Patients with Difficult-to-Treat Blood Cancers at ASH 2023
November 02, 2023 09:43 ET | Source: Wugen

Wugen to Present New Clinical Data for WU-CART-007 and Preclinical Data for WU-NK-101, Two Investigational Allogeneic Cell Therapies for Challenging Hematologic Cancers, at American Society of Hematology Annual Meeting & Exposition

-- Oral Presentation Highlights Latest Clinical Findings from First Global, In-Human Phase 1/2 Dose-Escalation Study of Anti-CD7 Off-the-Shelf Allogeneic CAR-T Cell Therapy, WU-CART-007, in...